Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 12/2001

01.12.2001 | Adis New Drug Profile

Frovatriptan

verfasst von: Stephanie E. Easthope, Karen L. Goa

Erschienen in: CNS Drugs | Ausgabe 12/2001

Einloggen, um Zugang zu erhalten

Abstract

  • ▴ Frovatriptan, a new serotonin receptor agonist developed for the acute treatment of migraine, has high affinity for serotonin 5-HT1B and 5-HT1D receptor subtypes and is a potent stimulator of contraction in human basilar arteries.
  • ▴ Along terminal elimination half-life (≈26 hours) is a distinctive pharmacokinetic feature of frovatriptan which appears to be independent of dose, age, gender and renal function.
  • ▴ A single oral dose of frovatriptan 2.5mg was effective in the acute treatment of migraine providing meaningful relief within 2 hours to approximately twice as many recipients as placebo in clinical trials.
  • ▴ Consistent relief of migraine symptoms was achieved in patients who treated a number of consecutive attacks with frovatriptan and the incidence of 24-hour migraine recurrence was reduced.
  • ▴ Frovatriptan was well tolerated in clinical trials, with the overall incidence of adverse events occurring with frovatriptan 2.5mg only slightly higher than that reported with placebo. Mild to moderate fatigue, nausea and paraesthesia were the most commonly reported drug-related adverse events
Fußnoten
1
Menstrually associated migraine (MAM) is defined as a migraine attack occurring between the 3 days prior to and 4 days after the first day of menstruation.
 
Literatur
1.
2.
Diener H-C, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drugs 1998 Nov; 56(5): 811–24PubMedCrossRef
3.
4.
Longmore J, Shaw D, Smith D, et al. Differential distribution of 5HT1d- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 1997; 17: 833–42PubMedCrossRef
5.
Brown AM, Parsons AA, Raval P, et al. SB 209509 (VML 251), a potent constrictor of rabbit basilar artery with high affinity and selectivity for human 5-HT1d receptors [abstract]. Br J Pharmacol 1996 Oct; 119 Proc Suppl.: 11OP
6.
Brown AM, Ho M, Thomas DR, et al. Comparison of functional effects of frovatriptan* (VML 251), sumatriptan, and naratriptan on human recombinant 5-HT1 and 5-HT7 receptors [abstract]. Headache 1998 May; 38: 376
7.
Eglen RM, Jasper JR, Chang DJ, et al. The 5-HT7 receptor: orphan found. TiPS 1997 Apr; 18: 104–7PubMed
8.
Parsons AA, Raval P, Smith S, et al. Effects of the novel high-affinity 5-HT1B/1D-receptor ligand frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol 1998 Aug; 32: 220–4PubMedCrossRef
9.
Parsons AA, Parker SG, Raval P, et al. Comparison of the cardiovascular effects of the novel 5-HT1B/1Dreceptor agonist, SB 209509 (VML251), and sumatriptan in dogs. J Cardiovasc Pharmacol 1997 Jul; 30: 136–41PubMedCrossRef
10.
Keywood C. The effects of ascending doses of oral frovatriptan* (VML 251 /SB 209509), a potent selective 5HT1b/1d agonist, for the acute treatment of migraine on the cardiovascular system of healthy male volunteers [abstract]. Headache 1998 May; 38(5): 388
11.
Elkind A, McDaris HL, Satin L, et al. Cardiovascular safety of frovatriptan in patients at high risk of or with known coronary artery disease during a migraine attack [abstract]. Cephalalgia 1999 May; 19: 365
12.
Buchan P, Keywood C, Ward C. The pharmacokinetics of frovatriptan (VML 251/SB 209509), a potent, selective 5-HT1B/1D agonist, following a single dose administration by oral and intravenous routes to healthy male and female volunteers [poster]. 40th Annual Scientific Meeting of the American Association for the Study of Headache; 1998 Jun 26–28; San Francisco.
13.
Buchan P. The pharmacokinetics of frovatriptan* (VML 251/ SB 209509), a potent selective 5-HT1b/1dagonist, following single dose administration by oral and intravenous routes to healthy male and female volunteers [abstract]. Headache 1998 May; 38(5): 376
14.
Buchan P. Can blood cell binding explain the long half-life of frovatriptan? [abstract P2076]. Eur J Neurol 2000; 7 Suppl. 3:86
15.
Buchan P, Ward C, Zeig S. Frovatriptan pharmacokinetics are unaffected during a migraine attack [abstract P433]. Eur J Neurol 1999; 6 Suppl. 3: 137
16.
Buchan P, Keywood C, Ward C. Pharmacokinetics of frovatriptan (VML 251/SB 209509) in healthy young and elderly male and female subjects [poster]. 3rd Congress of the European Federation of Neurological Societies; 1998 Sep 18–25; Seville.
17.
Buchan P. In. vitro. metabolism of frovatriptan [abstract P2057]. Eur J Neurol 2000; 7 Suppl. 3: 81
18.
Buchan P. Effects of alcohol, smoking and oral contraceptives on the pharmacokinetics of frovatriptan [abstract P2077]. Eur J Neurol 2000; 7 Suppl. 3: 86
19.
Cohen AF, van der Post J, Sacks S, et al. Pharmacokinetics of frovatriptan in patients with renal impairment [abstract]. Cephalalgia 1999 May; 19: 365
20.
Cohen AF, van der Post J, Sacks S, et al. Pharmacokinetics of frovatriptan in patients with renal impairment [poster]. 9th Congress of the International Headache Society; 1999 Jun 22-26; Barcelona.
21.
Buchan P, Ward C, Oliver SD. Lack of clinically significant interactions between frovatriptan and ergotamine [abstract]. Cephalalgia 1999 May; 19: 364
22.
Wade A, Buchan P, Mant T, et al. Frovatriptan has no clinically significant interaction with fluvoxamine [abstract]. Cephalalgia 2001; 21: 427
23.
Buchan P, Ward C, Stewart AJ. Propranolol has minimal effects on the pharmacokinetics and safety of frovatriptan [abstract]. Cephalalgia 1999 May; 19: 364–5
24.
Buchan P, Ward C, Stewart AJ. The effect of propanolol on the pharmacokinetic and safety profiles of frovatriptan [poster]. 9th Congress of the International Headache Society; 1999 Jun 22–26; Barcelona.
25.
Buchan P, Ward C, Freestone S. Lack of interaction between frovatriptan and monoamine oxidase inhibitor [abstract]. Cephalalgia 1999 May; 19: 364
26.
Buchan P, Ward C, Freestone S. Lack of interaction between frovatriptan and the monoamine oxidase inhibitor, moclo-bemide [poster]. 9th Congress of the International Headache Society; 1999 Jun 22–26; Barcelona.
27.
Ryan R, Keywood C. A preliminary study of frovatriptan (VML251), a potent cerebroselective 5-hydroxytryptamine (5-HT)1b/1d agonist for the acute treatment of migraine [abstract MTH1]. Eur J Neurol 1998 Sep; 5 Suppl. 3: S46
28.
Goldstein J, Elkind A, Keywood C, et al. A low-dose rangefinding study of frovatriptan, a potent selective 5HT1D agonist for the acute treatment of migraine [abstract]. Cephalalgia 1998 Jul–Aug; 18: 410
29.
Ryan R, Keywood C. Frovatriptan: review of efficacy in acute treatment of migraine [abstract]. Headache 2000 May; 40: 429
30.
Spierings ELH, Keywood C, on behalf of the VML 251/96/08 Investigators. Consistent migraine relief with frovatriptan, a novel 5HT1B/1Dagonist [abstract]. Cephalalgia 1999 May; 19: 367
31.
Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1–96
32.
International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine, 1st ed. Cephalalgia 1991 Feb; 11: 1–12CrossRef
33.
Goldstein J, Keywood C, Hutchison J. Low 24-hour migraine recurrence during treatment with frovatriptan [abstract]. Cephalalgia 1999 May; 19: 365–6
34.
Ryan R, Keywood C. Apreliminary study of frovatriptan (VML 251), a cerebroselective 5-HT1B/1Dagonist for the acute treatment of migraine [poster]. 3rd Congress of the European Federation of Neurological Societies; 1998 Sep 18–25; Seville.
35.
Goldstein J, Keywood C. A study of the efficacy and safety of low doses of frovatriptan (VML 251), apotent, cerebroselective 5-HT1B/1Dagonist, in the acute treatment of migraine [poster]. 3rd Congress of the European Federation of Neurological Societies; 1998 Sep 18–25; Seville.
36.
McDaris HL, Hutchison J on behalf of the frovatriptan PIII investigators. Frovatriptan — a review of overall clinical efficacy [poster]. 9th Congress of the International Headache Society; 1999 Jun 22–26; Barcelona.
37.
Spierings ELH, KeywoodC, VML 251/96/08 Investigators. Frovatriptan, a novel 5-HTIB/ID agonist, provides consistent relief of migraine [abstract P437]. Eur J Neurol 1999 Sep; 6 Suppl. 3: 139
38.
Geraud G. Migraine headache recurrence: relationship to clinical, pharmacological and pharmacokinetic properties of triptans [abstract]. Cephalalgia 2001; 21: 406
39.
MacGregor EA, Keywood C. Frovatriptan is effective in men-strually associated migraine [poster]. Headache World 2000; 2000 Sep 3–7; London.
40.
Spierings ELH, Hutchison J. Frovatriptan — a review of safety and tolerability [poster]. 9th Congress of the International Headache Society; 1999 Jun 22–26; Seville.
41.
Geraud G, Keywood C. Tolerability of frovatriptan during short-and long-term use for migraine and comparison with sumatriptan [poster]. Headache World 2000; 2000 Sep 3–7; London
42.
43.
Metadaten
Titel
Frovatriptan
verfasst von
Stephanie E. Easthope
Karen L. Goa
Publikationsdatum
01.12.2001
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 12/2001
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200115120-00006

Weitere Artikel der Ausgabe 12/2001

CNS Drugs 12/2001 Zur Ausgabe

Leading Article

Magnesium for Neuroprotection in Ischaemic Stroke

Leading Article

Bacterial Meningitis

Adis New Drug Profile

Frovatriptan

Review Article

Future Prospects for the Drug Treatment of Epilepsy

Therapy In Practice

Diagnosis and Treatment of Nonconvulsive Status Epilepticus

Adis New Drug Profile

Frovatriptan

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise